Bladder Cancer News
In current urological practice, clinicians decide whether to place a ureteral stent or nephrostomy, but evidence-based treatment guidance is needed.
The accelerated approval was based on data from the multicenter, open-label, phase 2 TROPHY study.
Seminal vesicle-sparing radical cystectomy improved functional results over a median of 64 months without compromising oncologic outcomes, according to investigators.
High-risk NMIBC progression more than doubled healthcare costs over 5 years compared with no progression, a study found.
In 2016, the FDA granted accelerated approval to Tecentriq for prior-platinum treated metastatic urothelial carcinoma based on tumor response rate and duration of response.
Investigators found that the odds of locoregional recurrence of muscle-invasive bladder cancer following radical cystectomy depend on disease risk category.
A new algorithm developed by Canadian investigators aims to address underuse of cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Under the accelerated approval program, if a confirmatory trial does not show clinical benefit, the FDA can take steps to remove the drug or indication.
AstraZeneca has voluntarily withdrawn durvalumab’s (Imfinzi’s) indication for adults with locally advanced or metastatic bladder cancer.
In an online survey, 17.2% of patients with genitourinary cancers reported they delayed or avoided seeking medical care because of the COVID-19 pandemic.
Vicineum has been awarded a priority review for patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
Researchers analyzed data from patients with metastatic urothelial cancer to determine whether tumor mutation burden was associated with immune-related AEs among patients treated with immune checkpoint inhibitors.
Researchers sought to identify social disparities in diagnosis and treatment among patients with bladder cancer.
Using porcine bladders, researchers investigated whether bladder pressure affects the extent to which gemcitabine penetrates the bladder wall with this treatment modality.
Investigators studied whether sexual orientation affects screening for prevalent gender-specific cancers including prostate, breast, and cervical cancer.
Lythgoe et al studied patterns of race reporting in genitourinary (GU) cancer trials.
Patients with metastatic urothelial carcinoma have significantly longer overall survival when treated with a combination of radiotherapy and chemotherapy compared with chemotherapy alone, a study found.
Study findings support surveillance for urethral recurrence after radical cystectomy.
Powles et al present the primary results from the phase 3 EV-301 trial in advanced urothelial carcinoma.
CheckMate 274 investigators compared adjuvant nivolumab with placebo (PBO) in patients with MIUC who received cisplatin prior to radical surgery.